Cargando…
Dupilumab Provides Significant Clinical Benefit in a Phase 3 Trial in Adolescents with Uncontrolled Atopic Dermatitis Irrespective of Prior Systemic Immunosuppressant Use
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Society for Publication of Acta Dermato-Venereologica
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9413654/ https://www.ncbi.nlm.nih.gov/pubmed/34043020 http://dx.doi.org/10.2340/00015555-3848 |
| _version_ | 1784775802545504256 |
|---|---|
| author | DELEURAN, Mette MARCOUX, Danielle DE BRUIN-WELLER, Marjolein S. IRVINE, Alan D. BASELGA, Eulalia AHN, Kangmo CASTRO, Ana Paula BANSAL, Ashish CHAO, Jingdong BÉGO-LE BAGOUSSE, Gaëlle ROSSI, Ana B. |
| author_facet | DELEURAN, Mette MARCOUX, Danielle DE BRUIN-WELLER, Marjolein S. IRVINE, Alan D. BASELGA, Eulalia AHN, Kangmo CASTRO, Ana Paula BANSAL, Ashish CHAO, Jingdong BÉGO-LE BAGOUSSE, Gaëlle ROSSI, Ana B. |
| author_sort | DELEURAN, Mette |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9413654 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Society for Publication of Acta Dermato-Venereologica |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-94136542022-10-20 Dupilumab Provides Significant Clinical Benefit in a Phase 3 Trial in Adolescents with Uncontrolled Atopic Dermatitis Irrespective of Prior Systemic Immunosuppressant Use DELEURAN, Mette MARCOUX, Danielle DE BRUIN-WELLER, Marjolein S. IRVINE, Alan D. BASELGA, Eulalia AHN, Kangmo CASTRO, Ana Paula BANSAL, Ashish CHAO, Jingdong BÉGO-LE BAGOUSSE, Gaëlle ROSSI, Ana B. Acta Derm Venereol Short Communication Society for Publication of Acta Dermato-Venereologica 2021-07-15 /pmc/articles/PMC9413654/ /pubmed/34043020 http://dx.doi.org/10.2340/00015555-3848 Text en © 2021 Acta Dermato-Venereologica https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the CC BY-NC license |
| spellingShingle | Short Communication DELEURAN, Mette MARCOUX, Danielle DE BRUIN-WELLER, Marjolein S. IRVINE, Alan D. BASELGA, Eulalia AHN, Kangmo CASTRO, Ana Paula BANSAL, Ashish CHAO, Jingdong BÉGO-LE BAGOUSSE, Gaëlle ROSSI, Ana B. Dupilumab Provides Significant Clinical Benefit in a Phase 3 Trial in Adolescents with Uncontrolled Atopic Dermatitis Irrespective of Prior Systemic Immunosuppressant Use |
| title | Dupilumab Provides Significant Clinical Benefit in a Phase 3 Trial in Adolescents with Uncontrolled Atopic Dermatitis Irrespective of Prior Systemic Immunosuppressant Use |
| title_full | Dupilumab Provides Significant Clinical Benefit in a Phase 3 Trial in Adolescents with Uncontrolled Atopic Dermatitis Irrespective of Prior Systemic Immunosuppressant Use |
| title_fullStr | Dupilumab Provides Significant Clinical Benefit in a Phase 3 Trial in Adolescents with Uncontrolled Atopic Dermatitis Irrespective of Prior Systemic Immunosuppressant Use |
| title_full_unstemmed | Dupilumab Provides Significant Clinical Benefit in a Phase 3 Trial in Adolescents with Uncontrolled Atopic Dermatitis Irrespective of Prior Systemic Immunosuppressant Use |
| title_short | Dupilumab Provides Significant Clinical Benefit in a Phase 3 Trial in Adolescents with Uncontrolled Atopic Dermatitis Irrespective of Prior Systemic Immunosuppressant Use |
| title_sort | dupilumab provides significant clinical benefit in a phase 3 trial in adolescents with uncontrolled atopic dermatitis irrespective of prior systemic immunosuppressant use |
| topic | Short Communication |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9413654/ https://www.ncbi.nlm.nih.gov/pubmed/34043020 http://dx.doi.org/10.2340/00015555-3848 |
| work_keys_str_mv | AT deleuranmette dupilumabprovidessignificantclinicalbenefitinaphase3trialinadolescentswithuncontrolledatopicdermatitisirrespectiveofpriorsystemicimmunosuppressantuse AT marcouxdanielle dupilumabprovidessignificantclinicalbenefitinaphase3trialinadolescentswithuncontrolledatopicdermatitisirrespectiveofpriorsystemicimmunosuppressantuse AT debruinwellermarjoleins dupilumabprovidessignificantclinicalbenefitinaphase3trialinadolescentswithuncontrolledatopicdermatitisirrespectiveofpriorsystemicimmunosuppressantuse AT irvinealand dupilumabprovidessignificantclinicalbenefitinaphase3trialinadolescentswithuncontrolledatopicdermatitisirrespectiveofpriorsystemicimmunosuppressantuse AT baselgaeulalia dupilumabprovidessignificantclinicalbenefitinaphase3trialinadolescentswithuncontrolledatopicdermatitisirrespectiveofpriorsystemicimmunosuppressantuse AT ahnkangmo dupilumabprovidessignificantclinicalbenefitinaphase3trialinadolescentswithuncontrolledatopicdermatitisirrespectiveofpriorsystemicimmunosuppressantuse AT castroanapaula dupilumabprovidessignificantclinicalbenefitinaphase3trialinadolescentswithuncontrolledatopicdermatitisirrespectiveofpriorsystemicimmunosuppressantuse AT bansalashish dupilumabprovidessignificantclinicalbenefitinaphase3trialinadolescentswithuncontrolledatopicdermatitisirrespectiveofpriorsystemicimmunosuppressantuse AT chaojingdong dupilumabprovidessignificantclinicalbenefitinaphase3trialinadolescentswithuncontrolledatopicdermatitisirrespectiveofpriorsystemicimmunosuppressantuse AT begolebagoussegaelle dupilumabprovidessignificantclinicalbenefitinaphase3trialinadolescentswithuncontrolledatopicdermatitisirrespectiveofpriorsystemicimmunosuppressantuse AT rossianab dupilumabprovidessignificantclinicalbenefitinaphase3trialinadolescentswithuncontrolledatopicdermatitisirrespectiveofpriorsystemicimmunosuppressantuse |